Skin lesions in chronic myeloid leukemia patients during dasatinib treatment

Skin lesions in chronic myeloid leukemia patients during dasatinib treatment

Francesco Tarantini,1 Luisa Anelli,1 Giuseppe Ingravallo,1 Immacolata Attolico,1 Antonella Zagaria,1 Antonella Russo Rossi,1 Lucia Lospalluti,2 Tamara Bufano,2 Giovanni Zanframundo,2 Eugenio Maiorano,1 Giorgina Specchia,1 Francesco Albano11Department of Emergency and Organ Transplantation (D.E.T.O.)...

Full description

Bibliographic Details
Main Authors:	Tarantini F, Anelli L, Ingravallo G, Attolico I, Zagaria A, Russo Rossi A, Lospalluti L, Bufano T, Zanframundo G, Maiorano E, Specchia G, Albano F
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-08-01
Series:	Cancer Management and Research
Subjects:	inhibitor tyrosine kinase skin lesions chronic myeloid leukemia CD8+ lymphocytes dasatinib;
Online Access:	https://www.dovepress.com/skin-lesions-in-chronic-myeloid-leukemia-patients-during-dasatinib-tre-peer-reviewed-article-CMAR

Similar Items

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
by: Keskin D, et al.
Published: (2016-10-01)

Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia
by: Gadó Klára, et al.
Published: (2012-07-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: a case report
by: Naoki Oshima, et al.
Published: (2021-01-01)

Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review
by: Chao‐Chin Hsu, et al.
Published: (2021-06-01)

Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients
by: Beatriz Colom-Fernández, et al.
Published: (2019-11-01)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
by: Mario Tiribelli, et al.
Published: (2019-08-01)

Resistant Bilateral Chylous Effusion as a Late Adverse Effect of Dasatinib Treatment in Chronic Myeloid Leukaemia
by: Emine Zengin, et al.
Published: (2019-08-01)

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
by: Alessandra Iurlo, et al.
Published: (2021-02-01)

First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
by: Chen KK, et al.
Published: (2018-09-01)

Management of Chronic Myeloid Leukemia Patients During Pregnancy (Analysis of Literature and Practical Recommendations)
by: EYu Chelysheva, et al.
Published: (2019-03-01)

Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase
by: Ol'ga Yur'evna Vinogradova, et al.
Published: (2009-07-01)

A Case Report of BCR-ABL-JAK2-Positive Chronic Myeloid Leukemia with Complete Hematological and Major Molecular Response to Dasatinib
by: Elrazi Awadelkarim Hamid Ali, et al.
Published: (2021-04-01)

Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia
by: Aya Nakaya, et al.
Published: (2018-09-01)

Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life
by: TI Ionova, et al.
Published: (2017-04-01)

Chronic Myeloid Leukemia: Long-Term Experience of Target Therapy
by: KM Abdulkadyrov, et al.
Published: (2016-01-01)

Drug‐induced interstitial lung disease associated with dasatinib coinciding with active tuberculosis
by: Nozomi Tani, et al.
Published: (2020-10-01)

Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
by: Claudio Cerchione, et al.
Published: (2021-03-01)

Dasatinib-induced hemorrhagic colitis complicated with cytomegalovirus infection
by: Aya Nakaya, et al.
Published: (2017-12-01)

Change of right ventricular systolic pressure can indicate dasatinib‐induced pulmonary arterial hypertension in chronic myeloid leukemia
by: Sung‐Eun Lee, et al.
Published: (2021-03-01)

The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis
by: Mealing Stuart, et al.
Published: (2013-02-01)

Hodgkin Lymphoma as a Secondary Neoplasm During Therapy for Chronic Myeloid Leukaemia: Case Report and Review of the Literature
by: Paczkowska E, et al.
Published: (2021-04-01)

Multiple Keratoacanthomas, Philadelphia Chromosome+ Acute Lymphoblastic Leukemia, and Dasatinib: A Case Report
by: Siddhant Thukral, et al.
Published: (2015-11-01)

Economic evaluation of dasatinib in the treatment of chronic myeloid leukemia patients resistant to imatinib in Chile
by: Milva Caputo, et al.
Published: (2011-04-01)

Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?
by: Francesco Tarantini, et al.
Published: (2021-08-01)

Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
by: N. A. Avxentyev, et al.
Published: (2018-08-01)

Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
by: Massimo Breccia, et al.
Published: (2017-10-01)

Simultaneously occurred pleural and pericardial effusion related to dasatinib treatment: A case report
by: Serhat Sayın, et al.
Published: (2018-03-01)

Quality of life, symptom profile and clinical efficacy of second-line treatment with dasatinib in patients with imatinib-resistant or -intolerant chronic myeloid leukemia: results of 2-year follow-up
by: T. I. Ionova, et al.
Published: (2015-10-01)

Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion
by: Hao Zhang, et al.
Published: (2021-07-01)

Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
by: Olaf Beck, et al.
Published: (2020-03-01)

Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia
by: David N. Perdigoto, et al.
Published: (2017-10-01)

Complete response in advanced breast cancer patient treated with a combination of capecitabine, oral vinorelbine and dasatinib
by: V. Sgroi, et al.
Published: (2018-01-01)

Debating Frontline Therapy in Chronic Myeloid Leukemia
by: Xia Bi, et al.
Published: (2021-09-01)

Intracerebral Hemorrhage as the Initial Presentation of Chronic Myeloid Leukemia: A Case Report and Review of the Literature
by: Huafeng Wang, et al.
Published: (2020-10-01)

Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report
by: Gülten Taçoy, et al.
Published: (2015-01-01)

Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis
by: Kai Guo, et al.
Published: (2019-01-01)

Dasatinib-Induced Pulmonary Arterial Hypertension: A Case Report
by: Liu R, et al.
Published: (2021-08-01)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
by: Cumbo C, et al.
Published: (2020-05-01)

Cannot write session to /tmp/vufind_sessions/sess_8pfr4ccq4q0dq8o87c7i6uog8e